Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Lymperopoulos

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Pharmaceutics|June 27, 2024
Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory EffectsAnastasios Lymperopoulos, Jordana I Borges, Renee A Stoicovy
Therapeutic Advances in Cardiovascular Disease|September 19, 2023
The therapeutic potential of targeting cardiac RGS4Giselle Del Calvo, Teresa Baggio Lopez, Anastasios Lymperopoulos
International Journal of Molecular Sciences|July 24, 2021
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal GlandAnastasios Lymperopoulos, Jordana I Borges, Natalie Cora, et al.
Journal of Molecular and Cellular Cardiology|August 31, 2010
GRK2 as a novel gene therapy target in heart failureGiuseppe Rengo, Anastasios Lymperopoulos, Dario Leosco, et al.
Pharmacological Research|May 18, 2017
Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapyJennifer Maning, Shmuel Negussie, Michelle A Clark, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 22, 2018
A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcomaBarbara M Parker, John V Parker, Anastasios Lymperopoulos, et al.
Cureus|September 14, 2020
Methotrexate for Cornual Ectopic PregnancyBarbara M Parker, Anupam K Gupta, Anastasios Lymperopoulos, et al.
Neuroscience Letters|May 30, 2006
Alpha2-adrenergic receptor subtype-specific activation of NF-kappaB in PC12 cellsAnastasios Lymperopoulos, Georgios Karkoulias, Walter J Koch, et al.
Journal of the American College of Cardiology|January 15, 2011
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levelsAnastasios Lymperopoulos, Giuseppe Rengo, Carmela Zincarelli, et al.
Cellular Signalling|August 16, 2005
alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFRGeorgios Karkoulias, Orthodoxia Mastrogianni, Anastasios Lymperopoulos, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Pharmaceutics|June 27, 2024
Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory EffectsAnastasios Lymperopoulos, Jordana I Borges, Renee A Stoicovy
Therapeutic Advances in Cardiovascular Disease|September 19, 2023
The therapeutic potential of targeting cardiac RGS4Giselle Del Calvo, Teresa Baggio Lopez, Anastasios Lymperopoulos
International Journal of Molecular Sciences|July 24, 2021
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal GlandAnastasios Lymperopoulos, Jordana I Borges, Natalie Cora, et al.
Journal of Molecular and Cellular Cardiology|August 31, 2010
GRK2 as a novel gene therapy target in heart failureGiuseppe Rengo, Anastasios Lymperopoulos, Dario Leosco, et al.
Pharmacological Research|May 18, 2017
Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapyJennifer Maning, Shmuel Negussie, Michelle A Clark, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 22, 2018
A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcomaBarbara M Parker, John V Parker, Anastasios Lymperopoulos, et al.
Cureus|September 14, 2020
Methotrexate for Cornual Ectopic PregnancyBarbara M Parker, Anupam K Gupta, Anastasios Lymperopoulos, et al.
Neuroscience Letters|May 30, 2006
Alpha2-adrenergic receptor subtype-specific activation of NF-kappaB in PC12 cellsAnastasios Lymperopoulos, Georgios Karkoulias, Walter J Koch, et al.
Journal of the American College of Cardiology|January 15, 2011
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levelsAnastasios Lymperopoulos, Giuseppe Rengo, Carmela Zincarelli, et al.
Cellular Signalling|August 16, 2005
alpha(2)-Adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFRGeorgios Karkoulias, Orthodoxia Mastrogianni, Anastasios Lymperopoulos, et al.
Pageof 11